Beam Therapeutics Inc.
Company Stats
- Market Cap
- $2.5B
- as of Sep 30, 2026
- Shares Outstanding
- 103.3M
- Free Float
- 94.5%
Income Statement
- Revenue
- $139.7M
- Operating Income
- -$383.7M
- Net Income
- -$80.0M
- EBITDA
- -$361.4M
- Revenue Growth, 3Y
- 31.9%
- FCF Margin, 3Y Avg
- -289.0%
- FCF Margin, Worst Year
- -560.8%
Cash Flow
- Free Cash Flow
- -$360.0M
- FCF Yield
- -14.3%
- Owner FCF Yield
- -18.0%
Balance Sheet
- Cash & Equivalents
- $294.9M
Returns & Capital
- SBC, 3Y Avg
- $104.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $139.7M | -$360.0M | -257.7% |
| FY2024 | $63.5M | -$356.2M | -560.8% |
| FY2023 | $377.7M | -$182.9M | -48.4% |
| FY2022 | $60.9M | -$26.4M | -43.4% |
| FY2021 | $51.8M | -$113.1M | -218.1% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 4, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back